KCT0002975尚未招募未知
An open-label, multicenter, phase II study of PDR001 in patients with non-small cell lung cancer harboring KRAS/NRAS mutation or without actionable genetic abnormalities, detected using NGS platform
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •1. Subjects with histologically or cytologically confirmed, stage IV or recurrent NSCLC that carries a KRAS/NRAS mutation or no actionable mutation, which are identified by NGS.
- •2. Patients with no sensitizing EGFR mutations or ALK translocations
- •3. Squamous cell carcinoma and non-squamous cell carcinoma will be enrolled with 1:1 ratio for efficacy analysis according to histology
- •4. Subjects who did not treated with prior anti-PD-1 antibody nor anti-PD-L1 antibodies
- •5. ECOG performance status of 0 to 2
- •6. Male or female; = 18, < =80 years of age
- •7. Patients those who showed disease progression after one prior platinum-containing regimen
- •8. Subjects not treated with previous anti-PD-1 antibodies or anti-PD-L1 antibodies 1. Patients who have undergone platinum-containing assisted, preceding, or definitive chemotherapy for locally advanced lesions after 12 months of last treatment. However, CTCAE level 1 or lower due to anticancer therapy should be restored. Exceptions) Hair loss, peripheral neuropathy and this toxicity should be restored to a level 2 or lower.
- •9. Subjects with at least one measurable lesion (using RECIST 1.1 and irRC criteria)
- •10. Availability of tumor tissue biopsy for biomarker analysis. Archival tissue can be used. Fine-needle aspirates will not be acceptable.
- •11. Subjects who meet the following criteria:
- •- Absolute neutrophil count (ANC) = 1.5 x 10000000000/L
- •- Platelet count = 100 x 10000000000/L
- •- Serum creatinine = 1.5 x upper limit of normal (ULN)
- •- AST (SGOT) and ALT (SGPT) = 3 x upper limit of normal (ULN)
- •(If there is Liver Metastasis = 5 x upper limit of normal (ULN))
- •- Total bilirubin = 1.5 x upper limit of normal (ULN)
- •12. Life expectancy of >12 weeks on C1D1
- •13. Provision of written informed consent prior to any study specific procedures
排除标准
- •1. Patients who harboring EGFR mutation(s) and/or anaplastic lymphoma kinase (ALK) rearrangement will not be eligible for this trial.
- •2. Patients who have received more than 2 lines of prior systemic therapy, including cytotoxic agent or targeted agent
- •3. Previous treatment with immune oncologic agents
- •4. Any major operation or irradiation within 4 weeks of baseline disease assessment
- •5. Subjects with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms
- •6. Subjects with history of leptomeningeal metastasis
- •7. Other co-existing malignancies or malignancies diagnosed within the last 3 years with the exception of basal cell carcinoma or cervical cancer in situ. Any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC such as thyroid cancer.
- •8. Subjects with an uncontrolled major cardiovascular disease (including AMI within 12 months, unstable angina within 6 months, over NYHA class III congestive heart failure, congenital long QT syndrome (Corrected QT (QTcF) >470 ms using Fridericia’s correction on the screening ECG), 2° or more AV Block and uncontrolled hypertension)
- •9. Pregnant or lactating female
- •10. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
- •11. History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
- •12. Active, known or suspected autoimmune disease or a documented history of autoimmune disease, including ulcerative colitis and Crohn’s disease (Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll).
- •13. Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).
- •14. Patient has peripheral neuropathy greater than grade 2
- •15. Active HBV or HCV infection, HBV carrier without detectable HBV DNA is not excluded.
- •16. Known history of testing positive for Human Immunodeficiency Virus (HIV) infection
- •17. Any medical condition that would, in the investigator’s judgment, prevent the patient’s participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results.
- •18. Patients requiring chronic treatment with systemic steroid therapy or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steoids of < 10 mg/day prednisone are not prohibited.
- •19. Use of any live vaccines against infectious disease within 4 weeks of initiation of study treatment.
- •20. Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 150 days after the last dose of study treatment.
- •21. Sexually active males unless they use a condom during treatment and for 150 days after stopping study treatment .
- •22. Use of hematopoietic colony-stimulating growth factors (eg G
研究者
相似试验
进行中（未招募）
2 期
Phase II study for the treatment of recurrent and/or metastatic human papillomavirus (HPV16)-associated head and neck cancerRecurrent and/or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infectionCancerISRCTN15021247Syneos Health87
已完成
不适用
Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patientsnon small cell lung cancer1003866610028971lung cancerNL-OMON45593ovartis6
已完成
不适用
Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome (CPDR001X2105)bloodcell cancerbonemarrow cancer. AML: Acute myeloide leukemiaMDS: Myelodysplasia10024324NL-OMON55557ovartis5
进行中（未招募）
1 期
Study of RP1 alone and in combination with other therapies in patients with solid tumoursEUCTR2016-004548-12-ESReplimune Inc.300
进行中（未招募）
1 期
Study of RP1 alone and in combination with other therapies in patients with solid tumoursAdvanced solid tumoursMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2016-004548-12-GBReplimune Inc.293